This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. Weight loss can be a challenge, even for those who eat healthily and exercise regularly. Injectable weight loss medications — also ...

Teva Pharmaceuticals Inc. has received approval from the U.S. Food and Drug Administration for the first generic GLP-1 medication for weight loss, the Parsippany-based company announced Aug. 28. The ...

Generic Saxenda ® is the first-ever generic GLP-1 indicated for weight loss, addressing increased demand for this category of therapies in the U.S. market. This approval and launch add to Teva’s ...

Cipla USA Inc. the wholly owned subsidiary of Cipla Limited(BSE: 500087; NSE: CIPLA; and hereafter referred to as "Cipla") today announced the launch of Liraglutide Injection, 18 mg/3 mL (6 mg/mL) ...

Saxenda (liraglutide) is a GLP-1 agonist injection pen medication. It helps with sustained weight loss for adults with obesity, adults with overweight who are experiencing weight-related health issues ...

There are three main types of injectable weight loss drugs approved by the Food and Drug Administration (FDA): semaglutide, liraglutide and tirzepatide. These are administered either daily or weekly ...

Lexaria (LEXX) has now demonstrated, in distinct human clinical studies, clear reductions in AEs utilizing its patented DehydraTECH technology with all of the three major GLP-1 drugs sold in the world ...

Pharmacies can now prescribe a 'game-changer' weight-loss jab to tackle obesity. The UK is one of the most obese nation in Europe, with more than 35 million people - a majority of the country's ...

As the demand for affordable healthcare options grows, the pharmaceutical industry is increasingly focused on developing generic drugs to expand access and reduce costs. This trend is driving major ...